MIRM Stock Price, Mirum Pharmaceuticals Quote, Chart

Market Summary

USD24.62-1.21

Delayed

-4.68%

MIRM Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

MIRM Stock Price

View Fullscreen

MIRM RSI Chart

MIRM Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-7.68

Price/Sales (Trailing)

5.44

EV/EBITDA

-6.77

Price/Free Cashflow

-55.24

MIRM Price/Sales (Trailing)

MIRM Profitability

EBT Margin

-70.16%

Return on Equity

-67.59%

Return on Assets

-24.32%

Free Cashflow Yield

-1.81%

MIRM Fundamentals

MIRM Revenue

Revenue (TTM)

224.0M

Rev. Growth (Yr)

119.07%

Rev. Growth (Qtr)

-0.48%

MIRM Earnings

Earnings (TTM)

-158.6M

Earnings Growth (Yr)

16.1%

Earnings Growth (Qtr)

29.11%

Breaking Down MIRM Revenue

52 Week Range

24.2333.39

(Low)(High)

Last 7 days

1.1%

Last 30 days

-1.2%

Last 90 days

-7.5%

Trailing 12 Months

-1.2%

How does MIRM drawdown profile look like?

MIRM Financial Health

Current Ratio

3.68

MIRM Investor Care

Shares Dilution (1Y)

23.93%

Diluted EPS (TTM)

-3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	224.0M	0	0	0
2023	95.8M	115.8M	144.7M	186.4M
2022	33.6M	48.1M	62.6M	77.1M
2021	0	0	0	19.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mirum Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	bjerkholt eric	bought	49,600	24.8	2,000	chief financial officer
Mar 25, 2024	radovich peter	sold	-111,017	25.8	-4,303	president and coo
Mar 18, 2024	bjerkholt eric	bought	51,600	25.8	2,000	chief financial officer
Feb 02, 2024	howe jolanda	sold	-19,251	26.1918	-735	svp, global controller
Feb 02, 2024	radovich peter	sold	-46,883	26.1917	-1,790	president and coo
Feb 02, 2024	vig pamela	sold	-31,796	26.1918	-1,214	chief scientific officer
Feb 02, 2024	peetz christopher	sold	-157,491	26.1918	-6,013	chief executive officer
Feb 02, 2024	longpre lara	sold	-22,184	26.1918	-847	chief development officer
Jan 31, 2024	howe jolanda	acquired	-	-	1,772	svp, global controller
Jan 08, 2024	howe jolanda	sold	-14,802	28.0351	-528	svp, global controller

Which funds bought or sold MIRM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CenterBook Partners LP	added	136	1,545,890	3,076,120	0.21%
May 10, 2024	Campbell & CO Investment Adviser LLC	sold off	-100	-307,333	-	-%
May 10, 2024	BROWN BROTHERS HARRIMAN & CO	added	109	27,528	62,775	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-19.27	-8,581	18,840	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	234	2,231	3,442	-%
May 10, 2024	Covestor Ltd	unchanged	-	-	-	-%
May 10, 2024	CREDIT SUISSE AG/	added	4.69	-77,583	633,200	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	12.4	-8,997	197,820	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	31,149	31,149	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-10.68	-17,541,200	55,557,500	-%

Are Funds Buying or Selling MIRM?

Are funds buying MIRM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MIRM

No. of Funds

Unveiling Mirum Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eventide asset management, llc	5.78%	2,693,581	SC 13G/A
Feb 13, 2024	vanguard group inc	5.31%	2,476,244	SC 13G
Jan 31, 2024	blackrock inc.	5.4%	2,532,642	SC 13G
Dec 29, 2023	new enterprise associates 16, l.p.	-	0	SC 13D/A
Sep 18, 2023	biotechnology value fund l p	5.0%	2,329,616	SC 13G
Sep 05, 2023	frazier life sciences ix, l.p.	7.7%	3,566,912	SC 13D/A
Jun 23, 2023	new enterprise associates 16, l.p.	5.8%	2,186,243	SC 13D/A
May 03, 2023	flynn james e	0.00%	0	SC 13G/A
Apr 14, 2023	frazier life sciences ix, l.p.	9.4%	3,566,912	SC 13D/A
Mar 08, 2023	blackrock inc.	4.6%	1,677,907	SC 13G/A

Recent SEC filings of Mirum Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Mar 27, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Mirum Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	-2.86%	-28.22%	-57.66	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.52	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.76%	-10.51%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-4.04%	14.81%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Mirum Pharmaceuticals Inc News

Latest updates

Mirum Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-0.5%	69,222,000	69,554,000	47,725,000	37,497,000	31,598,000	27,906,000	18,780,000	17,484,000	12,892,000	8,946,000	5,000,000	11,000,000
Operating Expenses	-6.3%	95,690,000	102,139,000	72,873,000	61,770,000	58,746,000	62,067,000	51,662,000	48,925,000	45,628,000	48,713,000	47,824,000	48,401,000
S&GA Expenses	-1.2%	45,638,000	46,184,000	36,528,000	32,949,000	30,219,000	26,468,000	22,513,000	20,969,000	19,116,000	19,035,000	17,353,000	13,353,000
EBITDA Margin	22.3%	-0.60	-0.78	-1.08	-1.47	-1.37	-1.80	-0.73	-1.21	-2.06	-4.36	-	-
Income Taxes	177.3%	624,000	225,000	249,000	316,000	201,000	140,000	13,000	-6,570,000	11,000	12,000	9,000	11,000
Earnings Before Taxes	30.4%	-24,655,000	-35,434,000	-23,339,000	-73,722,000	-29,929,000	-36,291,000	-35,693,000	-33,492,000	-36,595,000	57,558,000	-47,099,000	-43,883,000
EBT Margin	19.5%	-0.70	-0.87	-1.13	-1.52	-1.41	-1.84	-0.77	-1.24	-2.08	-4.39	-	-
Net Income	29.1%	-25,279,000	-35,659,000	-23,588,000	-74,038,000	-30,130,000	-36,431,000	-35,706,000	-26,922,000	-36,606,000	57,546,000	-47,108,000	-43,894,000
Net Income Margin	19.3%	-0.71	-0.88	-1.13	-1.52	-1.35	-1.76	-0.67	-1.10	-2.08	-4.39	-	-
Free Cashflow	191.5%	15,199,000	-16,618,000	-18,221,000	-2,399,000	-33,815,000	-34,512,000	-26,044,000	-20,189,000	-39,669,000	-33,150,000	-34,220,000	-40,199,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	0.8%	652	647	651	444	334	353	364	297	278	295	235	248	222	241	142	156	173	147	158	104	52.00
Current Assets	0.5%	389	388	389	384	172	190	216	147	155	167	197	228	218	236	138	152	162	119	129	85.00	52.00
Cash Equivalents	5.8%	303	286	303	297	49.00	28.00	36.00	55.00	46.00	31.00	56.00	92.00	91.00	142	49.00	83.00	72.00	12.00	31.00	42.00	52.00
Inventory	-3.2%	22.00	22.00	22.00	9.00	7.00	6.00	7.00	5.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-29.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	-
Liabilities	4.9%	417	398	382	365	192	211	195	187	169	174	179	152	88.00	69.00	22.00	20.00	17.00	16.00	12.00	12.00	2.00
Current Liabilities	21.6%	106	87.00	75.00	58.00	49.00	65.00	51.00	45.00	35.00	43.00	50.00	29.00	35.00	18.00	19.00	17.00	14.00	13.00	11.00	11.00	2.00
Shareholder's Equity	-5.7%	235	249	269	79.00	141	142	169	111	109	120	56.00	96.00	134	172	120	136	156	130	146	-	-
Retained Earnings	-4.5%	-581	-556	-520	-497	-423	-392	-356	-320	-293	-257	-314	-267	-223	-173	-135	-114	-91.21	-69.90	-51.95	-36.86	-17.35
Additional Paid-In Capital	1.6%	816	803	791	576	564	535	526	432	403	377	371	363	358	345	256	250	247	200	198	2.00	0.00
Shares Outstanding	0.7%	47.00	47.00	47.00	38.00	38.00	37.00	35.00	32.00	31.00	30.00	30.00	30.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	830	-	-	-	609	-	0.00	-	-	-	-	-	244	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	191.5%	15,212	-16,618	-18,221	-2,331	-33,774	-34,270	-26,025	-20,172	-39,669	-33,147	-34,202	-40,199	-25,210	-36,279	-17,451	-16,994	-18,351	-13,698	-15,221	-8,017	-2,426
Share Based Compensation	17.8%	11,450	9,720	8,385	8,357	8,561	6,897	6,908	6,641	6,561	5,564	7,415	4,823	5,285	3,579	3,428	2,974	2,573	2,067	2,144	1,641	218
Cashflow From Investing	99.4%	-13.00	-2,000	-182,762	35,547	42,015	26,758	-79,529	23,971	36,500	108,023	-2,237	-24,455	-32,784	-4,946	-18,914	27,973	33,761	-5,144	-64,192	-58,401	-44.00
Cashflow From Financing	-32.2%	1,205	1,777	207,129	114,707	12,987	-329	86,066	5,246	18,104	615	345	65,912	6,594	134,508	2,096	25.00	44,659	-	68,417	58,760	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MIRM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 69,222	$ 31,598
Operating expenses:
Cost of sales	17,830	4,979
Research and development	32,222	23,548
Selling, general and administrative	45,638	30,219
Total operating expenses	95,690	58,746
Loss from operations	(26,468)	(27,148)
Other income (expense):
Interest income	3,633	2,272
Interest expense	(3,577)	(4,242)
Other income (expense), net	1,757	(811)
Net loss before provision for income taxes	(24,655)	(29,929)
Provision for income taxes	624	201
Net loss	$ (25,279)	$ (30,130)
Net loss per share, basic (in dollars per share)	$ (0.54)	$ (0.80)
Net loss per share, diluted (in dollars per share)	$ (0.54)	$ (0.80)
Weighted-average shares of common stock outstanding, basic (in shares)	46,927,550	37,675,306
Weighted-average shares of common stock outstanding, diluted (in shares)	46,927,550	37,675,306
Product sales, net
Revenue:
Total revenue	$ 68,917	$ 29,098
License and other revenue
Revenue:
Total revenue	$ 305	$ 2,500

MIRM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 302,843	$ 286,326
Accounts receivable	54,999	67,968
Inventory	21,606	22,312
Prepaid expenses and other current assets	10,017	10,935
Total current assets	389,465	387,541
Property and equipment, net	501	706
Operating lease right-of-use assets	680	1,284
Intangible assets, net	257,443	252,925
Other assets	3,873	4,165
Total assets	651,962	646,621
Current liabilities:
Accounts payable	15,983	7,416
Accrued expenses	89,568	78,544
Operating lease liabilities	358	1,104
Total current liabilities	105,909	87,064
Operating lease liabilities, noncurrent	328	617
Convertible notes payable, net	306,835	306,421
Other liabilities	4,287	3,849
Total liabilities	417,359	397,951
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 47,061,106 and 46,723,143 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	816,129	803,260
Accumulated deficit	(581,518)	(556,239)
Accumulated other comprehensive (loss) income	(13)	1,644
Total stockholders’ equity	234,603	248,670
Total liabilities and stockholders’ equity	$ 651,962	$ 646,621

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

CEO	Mr. Christopher Peetz
WEBSITE	mirumpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	213

Mirum Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Mirum Pharmaceuticals Inc? What does MIRM stand for in stocks?

MIRM is the stock ticker symbol of Mirum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirum Pharmaceuticals Inc (MIRM)?

As of Thu May 09 2024, market cap of Mirum Pharmaceuticals Inc is 1.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers. The fair value of Mirum Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mirum Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MIRM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mirum Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIRM is over valued or under valued. Whether Mirum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Mirum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRM.

What is Mirum Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, MIRM's PE ratio (Price to Earnings) is -7.68 and Price to Sales (PS) ratio is 5.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRM PE ratio will change depending on the future growth rate expectations of investors.